Multiple MicroPort® EP Catheters and Devices Approved in Uzbekistan

Shanghai, China – [Monday 21 September] 2020 – Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort® EP”) has recently obtained registration approval by the Uzbekistan Ministry of Health (MOH) for its proprietary catheters and other devices, marking its first entry into Uzbek market.

Arrhythmia is a common cardiovascular disease, and severe arrhythmia is the main cause of sudden cardiac death. Radiofrequency ablation surgery is one of the most important non-pharmacological treatments for arrhythmias. The approved catheters and devices, including FireMagic™ Cardiac RF Ablation Catheter, FireMagic™ 3D Irrigated Ablation Catheter, EasyFinder™ Fixed Curve Diagnostic Catheter, EasyFinder™ Steerable Curve Diagnostic Catheter, EasyLoop™ Circular Mapping Catheter, OptimAblate™ Tubing Set, Columbus™ External Reference Patch, FORLNK™ Cables, Columbus™ 3D EP Navigation System, Columbus™ Cardiac Electrophysiology Stimulator, OptimAblate™ Cardiac RF Generator and OptimAblate™ Irrigation Pump, are intended for the rapid diagnosis and effective treatment of arrhythmias.

As a major hub of the “Belt and Road” initiative, Uzbekistan has a population of more than 30 million people. Statistics show that approximately 1.5 million cases of acute or chronic cardiovascular disease are reported in Uzbekistan annually, with almost 20% of the population aged between 40 and 64 considered at risk. Cardiovascular disease is the leading cause of death, accounting for more than 60% of all deaths. The introduction of MicroPort® EP products into the Uzbek market is expected to provide more efficient and convenient treatment options for local patients suffering from arrhythmias.

In the future, MicroPort® EP will continue to respond actively to the “Belt and Road” health partnership initiative by building on its autonomous innovation and expanding into overseas markets. In doing so, it aims to support medical personnel in countries along the “Belt and Road” region to master and apply more advanced treatment methods for the benefit of more patients worldwide.